ClinicalTrials.gg
CompletedNCT02630316Updated Jul 27, 2022Results posted

Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

A Phase 2/3 interventional study of Inhaled Treprostinil and Placebo in Pulmonary Hypertension, Interstitial Lung Disease and Combined Pulmonary Fibrosis and Emphysema, sponsored by United Therapeutics. Completed at 97 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-27.

Sponsored by United Therapeutics · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
326
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 38 studies testing treprostinil in Hypertension, Pulmonary — 4 open to participants now, 4 under way, 1 of them phase 3. treprostinil · Hypertension, Pulmonary.

Enrollment
5th of 37
326 · median 32
Started
2017
with 3 others
Phase 2/3
2 of 38
none open now
Registered
21st of 38
by date
Lead sponsor
25 of 38
United Therapeutics

Among the 38 studies testing treprostinil in Hypertension, Pulmonary, this one is the 5th largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2017, is one of 2 in phase 2/3, and was the 21st registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

4 of the 38 studies testing treprostinil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 99 (61%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing treprostinil in Hypertension, Pulmonary, or all of them as a file.
02

Study summary

This was a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study included 326 patients at approximately 120 clinical trial centers. The treatment phase of the study lasted approximately 16 weeks. Patients who completed all required assessments were eligible to enter an open-label, extension study (RIN-PH-202).

Read the detailed description

Study RIN-PH-201 was a multicenter, randomized, double-blind, placebo controlled, 16 week, parallel group study designed to investigate the safety and efficacy of inhaled treprostinil in subjects with PH-ILD. Subjects initiated inhaled treprostinil or placebo at a dose of 3 breaths (18 mcg) 4 times daily (QID) (during waking hours). Study drug doses were maximized throughout the study. Dose escalations (additional 1 breath QID) could occur up to every 3 days with a target dosing regimen of 9 breaths (54 mcg) QID and a maximum dose of 12 breaths (72 mcg) QID, as clinically tolerated. Subjects were assessed during Screening and Baseline to determine eligibility for the study. Once eligible, 5 Treatment Phase visits to the clinic were required at Week 4, Week 8, Week 12, Week 15, and Week 16 (final study visit). An Early Termination (ET) Visit was conducted for subjects who discontinued prior to Week 16; all assessments planned for the final Week 16 Visit were conducted during the ET Visit, if applicable. Subjects were contacted at least weekly by telephone or email to assess tolerance to study drug, AEs, and changes to concomitant medications. Efficacy assessments consisted of 6-minute walk distance (6MWD), plasma N-terminal prohormone brain natriuretic peptide (NT-proBNP) concentration, and incidence of clinical worsening. Exploratory endpoints included change in St. George's Respiratory Questionnaire (SGRQ), change in distance saturation product (DSP), time to exacerbation of underlying lung disease, and pulmonary function tests (PFT). Safety assessments consisted of the development of AEs, vital signs, clinical laboratory parameters, ECG parameters, hospitalizations due to cardiopulmonary indications, exacerbations of underlying lung disease, and oxygenation. Subjects who remained on study drug, completed all assessments during the 16-week Treatment Phase, and met all eligibility criteria were eligible for the open-label extension study (RIN-PH-202). Additionally, subjects who withdrew from study drug prior to Week 16 due to clinical worsening and returned to the clinic for scheduled visits (excluding the Week 15 Visit) were eligible for RIN PH-202.

03

Conditions studied

  • Pulmonary Hypertension
  • Interstitial Lung Disease
  • Combined Pulmonary Fibrosis and Emphysema

Keywords

  • Treprostinil
  • PH
  • ILD
  • CPFE
  • 6 Minute Walk Test
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject voluntarily gave to participate in the study.
  2. Males and females aged 18 years or older at the time of informed consent.

    a. Females of were non-pregnant (as confirmed by a urine pregnancy test at screening) and non-lactating, and: i. Abstained from intercourse (when in line with their preferred and usual lifestyle), or ii. Used 2 medically acceptable, highly effective forms of for the duration of study, and at least 30 days after discontinuing study drug.

    b. Males with a partner of used condoms for the duration of treatment and for at least 48 hours after discontinuing study drug.

  3. The subject had a confirmed diagnosis of WHO Group 3 PH based on computed tomography (CT) imaging which was performed within 6 months prior to randomization and demonstrated evidence of diffuse parenchymal lung disease. Subjects had any form of ILD or CPFE.
  4. Subjects were required to have a right heart catheterization (RHC) within 1 year prior to randomization with the following documented parameters:

    1. Pulmonary vascular resistance (PVR) >3 Wood Units (WU) and
    2. A pulmonary capillary wedge pressure (PCWP) of \<15 mmHg and
    3. A mean pulmonary arterial pressure (mPAP) of >25 mmHg
  5. Baseline 6MWD ≥100 m.
  6. Subjects on a chronic medication for underlying lung disease (ie, pirfenidone, nintedanib, etc) were on a stable and optimized dose for ≥30 days prior to randomization.
  7. In the opinion of the Investigator, the subject was able to communicate effectively with study personnel, and was considered reliable, willing and likely to be cooperative with protocol requirements, including attending all study visits.
  8. Subjects with connective tissue disease (CTD) had a Baseline forced vital capacity (FVC) of \<70%.

Exclusion criteria

Exclusion criteria:

  1. The subject had a diagnosis of PAH or PH for reasons other than WHO Group 3 PH ILD as outlined in Inclusion Criterion 3.
  2. The subject showed intolerance or significant lack of efficacy to a prostacyclin or prostacyclin analogue that resulted in discontinuation or inability to effectively titrate that therapy.
  3. The subject received any PAH-approved therapy including: prostacyclin therapy (ie, epoprostenol, treprostinil, iloprost, or beraprost; except for acute vasoreactivity testing), prostacyclin (IP) receptor agonist (selexipag), endothelin receptor antagonist (ERA), phosphodiesterase type 5 inhibitor (PDE5-I), or soluble guanylate cyclase (sGC) stimulator within 60 days of randomization.
  4. The subject had evidence of left-sided heart disease as defined by:

    1. PCWP >15 mmHg
    2. \<40%. Note: Subjects with abnormal left ventricular function attributable entirely to impaired left ventricular filling due to the effects of right ventricular overload (ie, right ventricular hypertrophy and/or dilatation) were not excluded.
  5. The subject was receiving >10 L/min of oxygen supplementation by any mode of delivery at rest at Baseline.
  6. Current use of any inhaled tobacco/marijuana products or significant history of drug abuse at the time of .
  7. Exacerbation of underlying lung disease or active pulmonary or upper respiratory infection within 30 days of randomization.
  8. Initiation of pulmonary rehabilitation within 12 weeks prior to randomization.
  9. In the opinion of the Investigator, the subject had any condition that would interfere with the interpretation of study assessments or has any disease or condition (ie, peripheral vascular disease, musculoskeletal disorder, morbid obesity) that would likely be the primary limit to ambulation (as opposed to PH).
  10. Use of any drug/device, or participation in any investigational study with therapeutic intent within 30 days prior to randomization.
  11. Severe concomitant illness limiting (\<6 months).
  12. Acute pulmonary embolism within 90 days of randomization.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
326 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Matching placebo inhaled using an ultrasonic nebulizer four times daily

    Drug: Placebo

  • Active comparator
    Inhaled Treprostinil

    Active Treprostinil for inhalation solution (0.6 mg/mL) delivered via an ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath. Inhaled four times daily and titrated up to a maximum of 12 breaths four times daily

    Drug: Inhaled Treprostinil

Interventions

  • Inhaled treprostinil (6 mcg/breath) administered four times daily

    Also known as: Tyvaso

  • DrugPlacebo

    Placebo administered four times daily

06

What researchers measure

Primary outcomes

  1. Change in 6-minute Walk Distance (6MWD) Measured at Peak Exposure From Baseline to Week 16

    The intent of the 6MWD test is to evaluate exercise capacity associated with carrying out activities of daily living. Change in 6MWD from Baseline to Week 16, correlates with the current clinical standard for assessing patient functional status in the treatment of PH and is considered an objective measure of patient functional status. Subjects will be instructed to walk down a corridor at a comfortable speed as far as they can manage for six minutes. Peak exposure 6MWD will occur by conducting 6-minute walk test (6MWT) within 10 to 60 minutes after the most recent dose of study drug dose.

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Change in Plasma Concentration of N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) From Baseline to Week 16

    The NT-proBNP serum concentration is a useful biomarker associated with changes in right heart morphology and function. NT-proBNP serum concentration will be assessed to compare the severity of heart failure at Baseline and Week 16. Blood for NT-proBNP assessment must be drawn prior to conducting the 6MWT.

    Time frame: Baseline and Week 16

  2. Incidence of Clinical Worsening

    Subjects were monitored for clinical worsening from the time of randomization until 1 of the following criteria were met: hospitalization due to a cardiopulmonary indication; decrease in 6MWD \>15% from Baseline directly related to the disease under study, at 2 consecutive visits and at least 24 hours apart; death (all causes); or lung transplantation.

    Time frame: Baseline to Week 16

  3. Change in Peak 6-minute Walk Distance (6MWD) From Baseline to Week 12

    The intent of the 6MWD test is to evaluate exercise capacity associated with carrying out activities of daily living. Change in 6MWD from Baseline to Week 12, correlates with the current clinical standard for assessing patient functional status in the treatment of PH and is considered an objective measure of patient functional status. Subjects will be instructed to walk down a corridor at a comfortable speed as far as they can manage for six minutes. Peak exposure 6MWD will occur by conducting 6MWT within 10 to 60 minutes after the most recent dose of study drug dose.

    Time frame: Baseline and Week 12

  4. Change in Trough 6-minute Walk Distance (6MWD) From Baseline to Week 15

    The intent of the 6MWD test is to evaluate exercise capacity associated with carrying out activities of daily living. Change in 6MWD from Baseline to Week 15, correlates with the current clinical standard for assessing patient functional status in the treatment of PH and is considered an objective measure of patient functional status. Subjects will be instructed to walk down a corridor at a comfortable speed as far as they can manage for six minutes. Distance \<500 meters suggests considerable exercise limitation; Distance 500-800 meters suggests moderate limitation; Distance \>800 meters (with no rests) suggests mild or no limitation. Trough exposure 6MWD will occur by conducting 6-minute walk test (6MWT) at least four hours after the most recent study drug dose.

    Time frame: Baseline and Week 15

07

Results

Posted Jul 13, 2021

Participant flow

Participant flow — Overall Study
MilestonePlaceboInhaled Treprostinil
Started163163
Completed128130
Not completed3533

Outcome measures

PrimaryChange in 6-minute Walk Distance (6MWD) Measured at Peak Exposure From Baseline to Week 16

The intent of the 6MWD test is to evaluate exercise capacity associated with carrying out activities of daily living. Change in 6MWD from Baseline to Week 16, correlates with the current clinical standard for assessing patient functional status in the treatment of PH and is considered an objective measure of patient functional status. Subjects will be instructed to walk down a corridor at a comfortable speed as far as they can manage for six minutes. Peak exposure 6MWD will occur by conducting 6-minute walk test (6MWT) within 10 to 60 minutes after the most recent dose of study drug dose.

Time frame:
Baseline and Week 16
Reported as:
Median · meters
Change in 6-minute Walk Distance (6MWD) Measured at Peak Exposure From Baseline to Week 16
metersPlaceboInhaled Treprostinil
Change in 6-minute Walk Distance (6MWD) Measured at Peak Exposure From Baseline to Week 16-9.0 (-426 to 179)6.0 (-396 to 183)
Statistical analysis
  • Placebo vs Inhaled Treprostinil · ANCOVA · p = 0.0043 (p-value is obtained from nonparametric ANCOVA adjusted for Baseline 6MWD category.) · Hodges-lehmann: 21.0 · 95% CI 7.0 to 37.0
SecondaryChange in Plasma Concentration of N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) From Baseline to Week 16

The NT-proBNP serum concentration is a useful biomarker associated with changes in right heart morphology and function. NT-proBNP serum concentration will be assessed to compare the severity of heart failure at Baseline and Week 16. Blood for NT-proBNP assessment must be drawn prior to conducting the 6MWT.

Time frame:
Baseline and Week 16
Reported as:
Median · pg/mL
Change in Plasma Concentration of N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) From Baseline to Week 16
pg/mLPlaceboInhaled Treprostinil
Change in Plasma Concentration of N-terminal Pro-Brain Natriuretic Peptide (NT-proBNP) From Baseline to Week 1620.65 (-5483.3 to 87148.3)-22.65 (-11433.0 to 5373.1)
Statistical analysis
  • Placebo vs Inhaled Treprostinil · ANCOVA · p = <0.0001
SecondaryIncidence of Clinical Worsening

Subjects were monitored for clinical worsening from the time of randomization until 1 of the following criteria were met: hospitalization due to a cardiopulmonary indication; decrease in 6MWD \>15% from Baseline directly related to the disease under study, at 2 consecutive visits and at least 24 hours apart; death (all causes); or lung transplantation.

Time frame:
Baseline to Week 16
Reported as:
Count of participants · Participants
Incidence of Clinical Worsening
ParticipantsPlaceboInhaled Treprostinil
Incidence of Clinical Worsening5437
Statistical analysis
  • Placebo vs Inhaled Treprostinil · Log Rank · p = 0.0410 (p-value is calculated with log-rank test stratified by baseline 6MWD category.) · Hazard ratio (hr): 0.61 · 95% CI 0.40 to 0.92p-value was 0.0202 for the proportional hazard model. Hazard ratio, 95% confidence interval (CI), and p-values are calculated with proportional hazards model with treatment and Baseline 6MWD (continuous) as explanatory variables.
SecondaryChange in Peak 6-minute Walk Distance (6MWD) From Baseline to Week 12

The intent of the 6MWD test is to evaluate exercise capacity associated with carrying out activities of daily living. Change in 6MWD from Baseline to Week 12, correlates with the current clinical standard for assessing patient functional status in the treatment of PH and is considered an objective measure of patient functional status. Subjects will be instructed to walk down a corridor at a comfortable speed as far as they can manage for six minutes. Peak exposure 6MWD will occur by conducting 6MWT within 10 to 60 minutes after the most recent dose of study drug dose.

Time frame:
Baseline and Week 12
Reported as:
Median · meters
Change in Peak 6-minute Walk Distance (6MWD) From Baseline to Week 12
metersPlaceboInhaled Treprostinil
Change in Peak 6-minute Walk Distance (6MWD) From Baseline to Week 12-3.0 (-369 to 152)8.0 (-360 to 192)
Statistical analysis
  • Placebo vs Inhaled Treprostinil · ANCOVA · p = 0.0041 (p-value is obtained from nonparametric ANCOVA adjusted for Baseline 6MWD category) · Hodges-lehmann: 20.0 · 95% CI 7.0 to 34.0
SecondaryChange in Trough 6-minute Walk Distance (6MWD) From Baseline to Week 15

The intent of the 6MWD test is to evaluate exercise capacity associated with carrying out activities of daily living. Change in 6MWD from Baseline to Week 15, correlates with the current clinical standard for assessing patient functional status in the treatment of PH and is considered an objective measure of patient functional status. Subjects will be instructed to walk down a corridor at a comfortable speed as far as they can manage for six minutes. Distance \<500 meters suggests considerable exercise limitation; Distance 500-800 meters suggests moderate limitation; Distance \>800 meters (with no rests) suggests mild or no limitation. Trough exposure 6MWD will occur by conducting 6-minute walk test (6MWT) at least four hours after the most recent study drug dose.

Time frame:
Baseline and Week 15
Reported as:
Median · meter
Change in Trough 6-minute Walk Distance (6MWD) From Baseline to Week 15
meterPlaceboInhaled Treprostinil
Change in Trough 6-minute Walk Distance (6MWD) From Baseline to Week 15-9.0 (-369 to 180)0.0 (-396 to 144)
Statistical analysis
  • Placebo vs Inhaled Treprostinil · ANCOVA · p = 0.0432 (p-value is obtained from nonparametric ANCOVA adjusted for Baseline 6MWD category.) · Hodges-lehmann: 15.0 · 95% CI 0.0 to 29.0

Adverse events

Collected over AEs were recorded throughout the course of the study from the time that each subject signed the ICF until all study assessments were completed (16 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo12/163 (7.4%)42/163 (25.8%)149/163 (91.4%)
Active Inhaled Treprostinil10/163 (6.1%)38/163 (23.3%)152/163 (93.3%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventPlaceboActive Inhaled Treprostinil
PneumoniaInfections and infestations9/1631/163
DyspnoeaRespiratory, thoracic and mediastinal disorders7/1633/163
Acute respiratory failureRespiratory, thoracic and mediastinal disorders5/1634/163
Respiratory failureRespiratory, thoracic and mediastinal disorders5/1632/163
Fluid overloadMetabolism and nutrition disorders4/1630/163
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders4/1631/163
DeathGeneral disorders1/1633/163
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders2/1633/163
Acute myocardial infarctionCardiac disorders2/1631/163
Cardiac arrestCardiac disorders2/1631/163
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPlaceboActive Inhaled Treprostinil
CoughRespiratory, thoracic and mediastinal disorders54/16371/163
DyspnoeaRespiratory, thoracic and mediastinal disorders51/16341/163
HeadacheNervous system disorders32/16345/163
DizzinessNervous system disorders23/16330/163
NauseaGastrointestinal disorders26/16325/163
N-terminal prohormone brain natriuretic peptide increasedInvestigations25/1639/163
FatigueGeneral disorders23/16323/163
DiarrheaGastrointestinal disorders19/16322/163
Throat irritationRespiratory, thoracic and mediastinal disorders6/16320/163
Oropharyngeal painRespiratory, thoracic and mediastinal disorders4/16318/163

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboInhaled TreprostinilTotal
<=18 years000
Between 18 and 65 years4864112
>=65 years11599214
Age, Continuous
Age, Continuous(years)PlaceboInhaled TreprostinilTotal
Mean67.4 ± 11.265.6 ± 12.766.5 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboInhaled TreprostinilTotal
Female6885153
Male9578173
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboInhaled TreprostinilTotal
American Indian or Alaska Native123
Asian5712
Native Hawaiian or Other Pacific Islander000
Black or African American304171
White126112238
More than one race101
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(participants)PlaceboInhaled TreprostinilTotal
Puerto Rico202
United States161163324
Weight
Weight(kg)PlaceboInhaled TreprostinilTotal
Mean83.5 ± 20.683.9 ± 20.583.7 ± 20.5
Height
Height(cm)PlaceboInhaled TreprostinilTotal
Mean169.0 ± 9.4167.5 ± 10.3168.2 ± 9.9
BMI
BMI(kg/m^2)PlaceboInhaled TreprostinilTotal
Mean29.0 ± 5.930.0 ± 6.629.5 ± 6.3

8 further baseline measures are reported on the registry.

08

Study locations

97 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • IMC-Diagnostic & Medical Clinic
    Mobile, Alabama 36604, United States
  • Arizona Pulmonary Specialists, Ltd.
    Phoenix, Arizona 85012, United States
  • St. Joseph's Hospital and Medical Center
    Phoenix, Arizona 85013, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • Cedars-Sinai Medical Center, Advanced Health Sciences Pavilion
    Beverly Hills, California 90211, United States
  • University of California San Francisco - Fresno
    Fresno, California 93701, United States
  • University of California San Diego
    La Jolla, California 92093, United States
  • VA Long Beach Healthcare System
    Long Beach, California 90822, United States
  • University of Southern California Health Sciences
    Los Angeles, California 90033, United States
  • Department of Veterans Affairs Greater Los Angeles Healthcare System
    Los Angeles, California 90073, United States
  • Pacific Pulmonary Medical Group
    Riverside, California 92505, United States
  • Kaiser Permanente - Roseville
    Roseville, California 95825, United States
  • University of California Davis Medical Center
    Sacramento, California 95817, United States
  • Kaiser Permanente
    San Francisco, California 94115, United States
  • University of Colorado Hospital - Cardiac and Vascular Center
    Aurora, Colorado 80045, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • Yale New Haven Hospital
    New Haven, Connecticut 06510, United States
  • Medstar Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • MedStar Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • Florida Lung, Asthma & Sleep Specialists, P.A.
    Celebration, Florida 34747, United States
  • St. Francis Sleep, Allergy and Lung Institute
    Clearwater, Florida 33765, United States
  • University of Florida Clinical Research Center
    Gainesville, Florida 32610, United States
  • University of Florida College of Medicine, Jacksonville
    Jacksonville, Florida 32209, United States
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
  • St. Vincent's Health System
    Jacksonville, Florida 33204, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Florida Hospital
    Orlando, Florida 32804, United States
  • South Miami Heart Specialists
    South Miami, Florida 33143, United States
  • Tampa General Hospital Center of Research Excellence
    Tampa, Florida 33606, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • The Emory Clinic
    Atlanta, Georgia 30322, United States
  • Piedmont - Georgia Lung Associates
    Austell, Georgia 30106, United States
  • Wellstar Medical Group - Pulmonary Medicine
    Marietta, Georgia 30060, United States
  • Northwestern University School of Medicine
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Illinois at Chicago Hospital
    Chicago, Illinois 60612, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • U Health Physicians Advanced Heart and Lung Clinic
    Indianapolis, Indiana 46202, United States
  • Community Heart and Vascular Hospital East
    Indianapolis, Indiana 46250, United States
  • St. Vincent Medical Group, Inc.
    Indianapolis, Indiana 46260, United States
  • University of Iowa Hospitals & Clinics
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • University of Kentucky Medical Center
    Lexington, Kentucky 40536, United States
  • University of Louisville Clinical Trials Unit
    Louisville, Kentucky 40202, United States
  • Louisiana State University Health Sciences Center New Orleans
    New Orleans, Louisiana 70112, United States
  • Chest Medicine Associates
    South Portland, Maine 04106, United States
  • University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
  • Johns Hopkins University Pulmonary and Critical Care Medicine
    Baltimore, Maryland 21205, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • Spectrum Health Heart and Lung Specialized Care Clinic
    Grand Rapids, Michigan 49503, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • Saint Luke's Hospital of Kansas City
    Kansas City, Missouri 64111, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • The University of New Mexico Clinical and Translational Science Center
    Albuquerque, New Mexico 87131, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • New York Methodist Hospital
    Brooklyn, New York 11215, United States
  • Northwell Health
    New Hyde Park, New York 11040, United States
  • NYU Langone Medical Center
    New York, New York 10016, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • New York Presbyterian - Weill Cornell Medical Center
    New York, New York 10065, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Duke University Medical Center-Duke South Clinic
    Durham, North Carolina 27710, United States
  • Pinehurst Medical Clinic, Inc.
    Pinehurst, North Carolina 28374, United States
  • The Lindner Research Center at The Christ Hospital
    Cincinnati, Ohio 45219, United States
  • University of Cincinnati Health
    Cincinnati, Ohio 45267, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University Medical Center
    Columbus, Ohio 43221, United States
  • INTEGRIS Baptist Medical Center
    Oklahoma City, Oklahoma 73112, United States
  • Penn Medicine University City
    Philadelphia, Pennsylvania 19104, United States
  • Allegheny General Hospital
    Pittsburgh, Pennsylvania 15212, United States
  • UPMC Montifiore University Hospital
    Pittsburgh, Pennsylvania 15213, United States
  • AnMed Health Medical Center
    Anderson, South Carolina 29621, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Statcare Pulmonary Consultants
    Knoxville, Tennessee 37919, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Texas Tech University Health Sciences Center
    El Paso, Texas 79905, United States
  • Houston Methodist
    Houston, Texas 77030, United States
  • Memoral Hermann Hospital - Texas Medical Center
    Houston, Texas 77030, United States
  • Michael E. DeBakey VA Medical Center
    Houston, Texas 77030, United States
  • The University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
  • Vermont Lung Center
    Colchester, Vermont 05446, United States
  • Inova Fairfax Medical Campus
    Fairfax, Virginia 22042, United States
  • Sentara Norfolk General Hospital
    Norfolk, Virginia 23507, United States
  • Pulmonary Associates of Richmond
    Richmond, Virginia 23229, United States
  • University of Washington Medical Center
    Seattle, Washington 98195, United States
  • University of Wisconsin School of Medicine and Public Health
    Madison, Wisconsin 53792, United States
  • Aurora St. Luke's Medical Center
    Milwaukee, Wisconsin 53215, United States
  • Medical College of Wisconsin/Froedtert Hospital
    Milwaukee, Wisconsin 53226, United States
  • Auxilio Mutuo Hospital
    Guaynabo, 00968, Puerto Rico
09

References and documents

Publications

  • Nathan SD, Deng C, King CS, DuBrock HM, Elwing J, Rajagopal S, Rischard F, Sahay S, Broderick M, Shen E, Smith P, Tapson VF, Waxman AB. Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes. Chest. 2023 Feb;163(2):398-406. doi: 10.1016/j.chest.2022.09.007. Epub 2022 Sep 15. PubMed 36115497 ↗
  • Nathan SD, Waxman A, Rajagopal S, Case A, Johri S, DuBrock H, De La Zerda DJ, Sahay S, King C, Melendres-Groves L, Smith P, Shen E, Edwards LD, Nelsen A, Tapson VF. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. Lancet Respir Med. 2021 Nov;9(11):1266-1274. doi: 10.1016/S2213-2600(21)00165-X. Epub 2021 Jun 29. PubMed 34214475 ↗
  • Waxman A, Restrepo-Jaramillo R, Thenappan T, Ravichandran A, Engel P, Bajwa A, Allen R, Feldman J, Argula R, Smith P, Rollins K, Deng C, Peterson L, Bell H, Tapson V, Nathan SD. Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. N Engl J Med. 2021 Jan 28;384(4):325-334. doi: 10.1056/NEJMoa2008470. Epub 2021 Jan 13. PubMed 33440084 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2017 to primary completion in Dec 2019, 34 months.

Results were first posted in Jul 2021, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2015
First posted
Dec 15, 2015
StartActual
Feb 3, 2017
Primary completionActual
Dec 26, 2019
CompletionActual
Dec 26, 2019
Results first posted
Jul 13, 2021
Last update
Jul 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02630316
Responsible party
Sponsor
First posted
Dec 15, 2015
Start date
Feb 3, 2017
Primary completion
Dec 26, 2019
Completion
Dec 26, 2019
Results posted
Jul 13, 2021
Last update
Jul 27, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion